Science products and services provider Thermo Fisher Scientific Inc (NYSE:TMO) revealed on Thursday that it has received the CE mark in the European Union for its diagnostic test to detect nucleic acid from SARS-CoV-2, the virus that causes COVID-19.
Utilising the company's Applied Biosystems TaqPath Assay and real-time PCR technology, the test is designed to provide patient results within four hours of a sample being received by a lab, including the time for sample preparation and instrument analysis.
With the CE mark, Thermo Fisher assures its test complies with the European Union's In vitro Diagnostic Directive, which applies to products that are manufactured in or designed to be sold in the European Economic Area.
Additionally, the company has passed the US FDA's amended Emergency Use Authorization for its COVID-19 test that includes Applied Biosystems 7500 Fast Real-Time PCR System, the MagMax Viral/Pathogen Nucleic Acid Isolation Kit as well as Applied Biosystems COVID-19 Interpretive Software, to expand testing in the US from about 1,000 instruments to about 3,000 .
Concurrently, the company's diagnostic test has received the designated approvals in Canada, Singapore, India, Australia and New Zealand.
Thermo Fisher has established an online resource to find up-to-date information about its response to the COVID-19 pandemic at https://corporate.thermofisher.com/en/COVID-19.html.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT